ADHD: The Second Prototype
ADHD unites three BERM mechanisms — dopamine deficit in PFC, myelination delay via Cav1.2, and E/I shift via KCC2 — into a neurodevelopmental phenotype. ASD and ADHD share 30-50% comorbidity because they represent different points on the same Q-factor spectrum.
This page proposes ADHD as a second BERM prototype. While PFC maturation delay, dopamine disruption, and myelination timing are established ADHD mechanisms, linking them to EMF exposure is a BERM hypothesis requiring direct testing.
Three converging mechanisms
ADHD emerges when three BERM pathways converge on prefrontal cortex function: dopamine deficit, myelination delay, and E/I shift. Each mechanism is independently documented; their convergence on PFC explains the clinical phenotype.
DA↓ in PFC (VK19: striatum -25%)
EMF → Ca²⁺↑ → CaMKII disruption → DA synthesis↓ → PFC DA deficit → attention↓, inhibition↓
PFC requires OPTIMAL dopamine (Goldilocks principle): too low → ADHD; too high → psychosis. VK19 demonstrates striatal dopamine reduction of 25% under EMF exposure. DA synthesis requires CaMKII, which depends on precise Ca²⁺ signaling — EMF disrupts CaMKII → DA↓. The inverted-U dose-response of DA in PFC means even moderate depletion collapses executive function.
Myelination delay (VK20: Cav1.2→OPC)
EMF → Cav1.2 disruption → OPC maturation↓ → PFC myelination delayed → PFC matures 5 YEARS later
PFC is the LAST brain region to myelinate, completing only in the mid-20s. Shaw 2007 (PNAS) showed ADHD cortex reaches peak thickness 5 years later than controls. VK20 identifies the mechanism: Cav1.2 channels regulate oligodendrocyte precursor cell (OPC) maturation. EMF-induced Cav1.2 disruption delays OPC differentiation → myelination delay → PFC is the most vulnerable region because it myelinates last.
E/I shift (VK6: KCC2↓ + VK4: α2δ-1↑)
EMF → KCC2 maturation↓ + α2δ-1↑ → E/I↑ → impulse control↓
The same E/I imbalance mechanism as ASD but at a LOWER Q value: fewer seizures (epilepsy 5-10% vs. 38% in ASD), less sensory hypersensitivity, but impaired impulse control and sustained attention. KCC2 delay keeps GABA excitatory in PFC circuits responsible for behavioral inhibition. α2δ-1 upregulation adds excitatory drive.
ASD-ADHD spectrum
ASD and ADHD are not separate disorders but different positions on the same E/I spectrum, modulated by Q-factor value and regional vulnerability.
ASD + ADHD comorbidity: 30-50% — far too high for coincidence, expected if both share the same mechanistic root
Same mechanism (E/I↑), different Q values: ASD = high Q (epilepsy 38%), ADHD = moderate Q (epilepsy 5-10%)
CACNA1C variants modulate position on spectrum: gain-of-function → ASD features; partial disruption → ADHD features
Both respond to treatments targeting the same pathways: bumetanide (GABA polarity), atomoxetine (noradrenergic PFC rescue), behavioral therapies targeting executive function
Prevalence increase explained
ADHD prevalence has risen sharply since the 1990s. BERM identifies a convergence of EMF-driven and EMF-adjacent factors that compound the dopamine deficit.
EMF → DA↓
Direct dopamine synthesis reduction via CaMKII disruption (VK19). Increasing ambient EMF exposure correlates with the prevalence timeline.
Myelination delay
EMF → Cav1.2 → OPC maturation↓ → PFC development delayed. Earlier and more intense EMF exposure during development shifts the myelination curve.
GABA switch delay
EMF → KCC2↓ → GABA stays excitatory longer in PFC circuits → impulse control fails to develop on schedule.
LED screen time (compound)
Screen time is not just behavioral — LED screens emit intermediate-frequency EMF + blue light suppresses melatonin + low DA makes screens MORE rewarding (hyperbolic discounting). The EMF-driven DA deficit creates a vicious cycle: DA↓ → screens more rewarding → more screen time → more IF exposure → DA↓↓.
Pharmacological validation
ADHD medications correct the exact disruptions that BERM predicts EMF produces. This is convergent validation: if the mechanism is wrong, the drugs should not work the way they do.
Methylphenidate/amphetamine: increase DA in PFC → symptoms improve. These drugs directly compensate for the VK19 dopamine deficit.
Same Ca²⁺ cascade: DA synthesis requires CaMKII; EMF disrupts CaMKII → DA↓. Stimulants bypass the synthesis bottleneck by blocking reuptake/promoting release.
Atomoxetine: norepinephrine reuptake inhibitor → also improves PFC function. PFC uses both DA and NE; atomoxetine rescues the catecholamine deficit via a parallel pathway.
Guanfacine (α2A agonist): strengthens PFC network connectivity. Effective in ADHD because PFC networks are weakened by the same myelination delay VK20 identifies.
Derived prediction · L* level
This section describes predictions derived from the BERM framework that have not yet been directly tested. They are presented as testable hypotheses, not established findings.
Prediction E-NEW-24 (EMF reduction during PFC-critical developmental window reduces ADHD symptom severity in genetically susceptible children) is directly testable in a prospective cohort design.
See predictions →